Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS0101 and Pembrolizumab in First-Line HPV16+ Head and Neck Squamous Cell Carcinoma
NCT06790966Phase 3Terminated
- Sponsor
- PDS Biotech
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PDS0101 in head and neck squamous cell carcinoma (HNSCC), sponsored by PDS Biotech. Started May 2025; status: terminated.
02
Drugs
PDS0101
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06790966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790966.